US Army funds AndCare's gene probe
This article was originally published in Clinica
AndCare has received $750,000 from the US Army to fund its portable DNA biosensors research. The Army stresses that it is interested in commercial as well as military applications of the gene probe, says Dr Robert Henkens, AndCare's chairman and CSO. The company, based in Research Triangle Park, North Carolina, is developing a battery-operated, hand-held monitor that uses mass-produced, calibrated, disposable sensor electrodes.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.